Gemmer Asset Management LLC Biomarin Pharmaceutical Inc Transaction History

Gemmer Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 31, 2020	SELL	$79.55 - $124.22 $62,049 - $96,891	-780 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$71.37 - $96.85 $1,427 - $1,937	-20 Reduced 2.5%	780 $65,000
Q4 2019 Jan 17, 2020	SELL	$64.27 - $86.37 $128 - $172	-2 Reduced 0.25%	800 $68,000
Q3 2019 Oct 11, 2019	BUY	$67.4 - $85.11 $134 - $170	2 Added 0.25%	802 $54,000
Q3 2018 Oct 12, 2018	SELL	$93.92 - $105.72 $18,784 - $21,144	-200 Reduced 20.0%	800 $78,000
Q2 2018 Jul 18, 2018	SELL	$76.01 - $99.03 $53,207 - $69,321	-700 Reduced 41.18%	1,000 $94,000
Q1 2018 May 11, 2018	SELL	$77.67 - $92.63 $38,835 - $46,315	-500 Reduced 22.73%	1,700 $138,000
Q3 2017 Oct 12, 2017	BUY	$80.6 - $94.95 $177,320 - $208,890	2,200	2,200 $205,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.